Article R1123-54 of the French Public Health Code
For the research mentioned in 1° of Article L. 1121-1 involving the cell therapy preparations defined in Article L. 1243-1, the sponsor shall report to the Agence nationale de sécurité du médicament et des produits de santé any suspected serious unexpected adverse reactions occurring in France and outside national territory within the following time limits: 1° In the case of a serious unexpected adverse reaction resulting in death or life-threatening…